Results 31 to 40 of about 11,186 (206)

Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies [PDF]

, 2013
Background: This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries.
Cho Naing (492196), Vanessa Racloz (321919), Marcel Tanner (33894), Maxine Anne Whittaker (492197), Joon Wah Mak, Aung Kyan, Marcel Tanner, Naing, Cho, Maxine Anne Whittaker, Cho Naing, Naing Cho, Racloz, Vanessa, Racloz Vanessa, Whittaker, Maxine Anne, Vanessa Racloz, Joon Wah Mak (207190), Kyan Aung, Tanner, Marcel, Mak, Joon Wah, Mak Joon Wah, Simon Andrew Reid, Simon Andrew Reid (492199), Reid, Simon Andrew, Tanner Marcel, Reid Simon Andrew, Aung, Kyan, Whittaker Maxine Anne, Kyan Aung (492198)   +27 more
core   +1 more source

Dihydroartemisinin ameliorates cerebral I/R injury in rats via regulating VWF and autophagy-mediated SIRT1/FOXO1 pathway

Open Medicine, 2023
Dihydroartemisinin (DHA) has been found to inhibit the expression of von Willebrand factor (VWF), a marker of endothelial cell injury, but its mechanism in cerebral ischemia/reperfusion (I/R) injury remains obscure.
Duan Qi, Wu Junxia
doaj   +1 more source

RETRACTED: Dihydroartemisinin Suppresses the Tumorigenesis and Cycle Progression of Colorectal Cancer by Targeting CDK1/CCNB1/PLK1 Signaling

Frontiers in Oncology, 2021
Dihydroartemisinin (DHA), a well-known antimalarial drug, has been widely investigated for its antitumor effects in multiple malignancies. However, its effects and regulatory mechanisms in colorectal cancer (CRC) are still unproved.
You-Cai Yi, Rui Liang, Xiao-Yu Chen, Hui-Ning Fan, Ming Chen, Jing Zhang, Jin-Shui Zhu   +6 more
doaj   +1 more source

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. [PDF]

, 2007
OBJECTIVES: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. DESIGN: Randomized single-blinded clinical trial.
Staedke Sarah G, Wabwire-Mangen, F, Yeka Adoke, Rwakimari, JB, Dorsey, Grant, Rwakimari John B, Nosten François, Talisuna, Ambrose O, Dorsey Grant, Kamya, MR, Greenhouse Bryan, Rosenthal, PJ, Greenhouse, B, Rosenthal Philip J, Staedke, SG, Nosten, F, Lugemwa, Myers, Rosenthal, Philip J, Yeka, Adoke, Dorsey, G, Staedke, Sarah G, Greenhouse, Bryan, Rwakimari, John B, Bukirwa, H, Bukirwa, Hasifa, Lugemwa, M, Kamya Moses R, Lugemwa Myers, Kamya, Moses R, Bukirwa Hasifa, Wabwire-Mangen Fred, Talisuna Ambrose O, Wabwire-Mangen, Fred, Talisuna, AO, Nosten, François, Yeka, A   +35 more
core   +1 more source

Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling

Frontiers in Cell and Developmental Biology, 2020
Platinum-based regimens have been routinely used in the clinical treatment of patients with esophageal squamous cell carcinoma (ESCC). However, administration of these drugs is frequently accompanied by drug resistance.
Wei Cui, Tingting Fang, Zhaoheng Duan, Dongfang Xiang, Yanxia Wang, Mengsi Zhang, Fangzheng Zhai, Xiang Cui, Lang Yang   +8 more
doaj   +1 more source

Efficacy and safety of dihydroartemisinin-piperaquine [PDF]

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007
Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. Efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria.
Myint, H, Ashley, E, Day, N, Nosten, F, White, N   +4 more
openaire   +4 more sources

Susceptibility of cervical cancer to dihydroartemisinin-induced ferritinophagy-dependent ferroptosis

Frontiers in Molecular Biosciences, 2023
The clinical therapeutics of cervical cancer is limited due to the drug resistance and metastasis of tumor. As a novel target for antitumor therapy, ferroptosis is deemed to be more susceptible for those cancer cells with resistance to apoptosis and ...
Hanqiang Shi, Hanqiang Shi, Lie Xiong, Lie Xiong, Guang Yan, Shuqin Du, Shuqin Du, Jie Liu, Yanbo Shi, Yanbo Shi   +9 more
doaj   +1 more source

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. [PDF]

, 2010
BACKGROUND: Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia.
Faizullah Kaker, Dondorp Arjen M, Sasithon Pukrittayakamee, Dondorp, AM, Sue Lee, Woodrow, CJ, Singhasivanon Pratap, Pukrittayakamee Sasithon, Pukrittayakamee, S, Pratap Singhasivanon, Arjen M Dondorp, Nicholas PJ Day, Day, NP, Day Nicholas PJ, Charles J Woodrow, White Nicholas J, Lee, SJ, Singhasivanon, P, Awab, GR, Kaker Faizullah, Imwong Mallika, Dondorp, Adrianus, Nicholas J White, Mallika Imwong, Imwong, Mallika, Imwong, M, Day, Nicholas, White, NJ, White, Nicholas, Awab Ghulam, Ghulam Awab, Woodrow Charles J, Lee Sue, Kaker, F   +33 more
core   +1 more source

Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients [PDF]

, 2006
Background: Intra-rectal artesunate has been developed as a potentially life-saving treatment of severe malaria in rural village settings where administration of parenteral antimalarial drugs is not possible.
Mwenechanya, J, McIlleron Helen, Agbenyega, Tsiri, Molyneux, M, Olliaro, P, Miller, Raymond, Kyaw Win, Nosten Francois, Simpson, Julie A., Tembo, M, Simpson, Julie A, Ribeiro, Isabela, van Vugt, Michele, Weerasuriya, Kris, Molyneux Malcolm, Nicholas J White, Miller Raymond, Julie A Simpson, Pang, L, Pang, Lorrin, Gianni Di Perri, Simpson Julie A, White, Nicholas J., McIlleron, H, Francois Nosten, Mansor, Sharif, Perri, Gianni Di, Ward, Steve, Michele van Vugt, White, Nicholas J, Helen McIlleron, Ward Steve, Isabela Ribeiro, Sharif Mansor, Olliaro Piero, White Nicholas J, Simpson, JA, Perri, GD, Di Perri, Gianni, Di Perri, G, Piero Olliaro, Barnes, Karen I, Krudsood, S, Krishna, Sanjeev, Win, K, Navaratnam, Visweswaran, Barnes Karen I, White, NJ, van Vugt, M, Ward, S, Olliaro, Piero, Visweswaran Navaratnam, Navaratnam Visweswaran, Raymond Miller, James Mwenechanya, Molyneux, Malcolm, Sornchai Looareesuwan, Agbenyega, T, Krudsood, Srivicha, Agbenyega Tsiri, Folb, P, Mansor, S, Looareesuwan, S, van Vugt Michele, Looareesuwan, Sornchai, Perri Gianni Di, Tembo Madalitso, Lorrin Pang, Krudsood Srivicha, Gomes, M, Melba Gomes, Sanjeev Krishna, Julie A Simpson, Gomes, Melba, Win Kyaw, Navaratnam, V, Mansor Sharif, White, Nicholas, Folb Peter, Ribeiro Isabela, Madalitso Tembo, McIlleron, Helen, Weerasuriya Kris, Barnes, KI, Kris Weerasuriya, Pang Lorrin, Tembo, Madalitso, Folb, Peter, Malcolm Molyneux, Ribeiro, I, Srivicha Krudsood, Barnes, Karen I., Looareesuwan Sornchai, Mwenechanya, James, Gomes Melba, Krishna Sanjeev, Nosten, F, Tsiri Agbenyega, Karen I Barnes, Mwenechanya James, Steve Ward, Krishna, S, Peter Folb, Win, Kyaw, Weerasuriya, K, Miller, R, Nosten, Francois   +106 more
core   +2 more sources

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. [PDF]

, 2006
BACKGROUND: Artemisinin-based combinations are judged the best treatments for multidrug-resistant Plasmodium falciparum malaria. Artesunate-mefloquine is widely recommended in southeast Asia, but its high cost and tolerability profile remain obstacles to
Kyaw, M K, Aye, KZ, Phe, O, Smithuis, F, Ashley, E, Kyaw, MK, Htet, L, Lwin, S, Barends, M, Ashley, E A, Stepniewska, K, Singtoroj, T, Lindegardh, N, Aye, K Z, White, NJ, White, Nicholas, White, N J   +16 more
core   +1 more source